Resonant Capital Advisors LLC Purchases 358 Shares of Boston Scientific Co. (NYSE:BSX)

Resonant Capital Advisors LLC raised its holdings in Boston Scientific Co. (NYSE:BSX) by 9.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,345 shares of the medical equipment provider’s stock after acquiring an additional 358 shares during the period. Resonant Capital Advisors LLC’s holdings in Boston Scientific were worth $388,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of BSX. Quarry LP bought a new position in Boston Scientific in the second quarter valued at approximately $33,000. Czech National Bank lifted its position in Boston Scientific by 7.1% in the 3rd quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock valued at $25,139,000 after acquiring an additional 19,833 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 39.9% in the 3rd quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock valued at $1,461,000 after purchasing an additional 4,972 shares during the period. Miracle Mile Advisors LLC lifted its holdings in shares of Boston Scientific by 4.0% in the third quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock valued at $440,000 after purchasing an additional 203 shares in the last quarter. Finally, Bank of New Hampshire boosted its position in shares of Boston Scientific by 52.6% during the third quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock worth $187,000 after buying an additional 770 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research reports. Canaccord Genuity Group boosted their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. TD Cowen boosted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. JPMorgan Chase & Co. boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. One investment analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Buy” and an average price target of $100.39.

Boston Scientific Trading Up 0.7 %

NYSE:BSX opened at $103.11 on Tuesday. Boston Scientific Co. has a 52 week low of $64.08 and a 52 week high of $104.25. The firm’s fifty day moving average is $93.47 and its 200-day moving average is $86.33. The firm has a market cap of $151.97 billion, a P/E ratio of 85.22, a P/E/G ratio of 2.68 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,989 shares of company stock valued at $2,702,261. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.